Search

everythinglearnresearchcommunity

for

Search:↓

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Deucravacitinib helped a man regrow hair and improve psoriasis.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

The treatment was ineffective in humans.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Oclacitinib maleate successfully treated alopecia in Andean bears.

JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.

Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.

JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.

Interest in JAK inhibitors for alopecia areata increased significantly after FDA approval, highlighting the need for patient education.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Nivolumab can cause hair loss as a rare side effect.

Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Nilotinib can cause generalized keratosis pilaris.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.